Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

Amgen’s Kyprolis wins ‘backbone therapy’ FDA nod after trumping Velcade in trial

Carly Helfand Back in March, Amgen's Kyprolis posted impressive results in a head-to-head trial with Takeda behemoth Velcade–and now, those results have helped it grab an ...

FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling

Tracy Staton For years, the Federal Trade Commission lamented the ever-growing number of pay-for-delay patent settlements–three in 2005, 14 in 2007, up to a record 40 in 2012–and ...

FDA not satisfied with Cadila’s efforts to fix warfarin production, even after 15 responses

Eric Palmer Cadila Healthcare last week got out in front of bad news by announcing it had received a warning letter from the FDA for two of its Indian plants but was ...

GSK whistleblower claims to have been fired after emailing CEO about Nicoderm concerns

Eric Palmer GlaxoSmithKline's Nicoderm products are among the leaders in helping smokers kick their habits. But a former employee says the study that showed their edge over ...

Threshold dumps two-thirds of its staff after a crushing failure

Damian Garde Threshold Pharmaceuticals, whose Merck KGaA-partnered oncology therapy failed in a pair of trials this month, is laying off the majority of its workers and rallying around ...

After a 7-year odyssey at the FDA, Merck finally wins an OK for Bridion

John Carroll For the past 7 years Merck has maintained a star rating by its program for Bridion (sugammadex), remaining convinced of its big market potential and staying upbeat after ...

Bayer looks to bone up in oncology after slipping behind rivals

Damian Garde German pharma giant Bayer is playing catch-up in the field of cancer treatments, expanding its efforts in hopes of cutting in on the burgeoning oncology market. FierceBiotech ...

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

Eric Palmer U.S.-based Catalent has halted production at a drug manufacturing facility in France at the request of regulators after several incidents in which it appears someone within ...

Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Eric Palmer Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...

Celyad set to scale up China-focused R&D activities after linking with Medisun

Nick Paul Taylor Cell therapy specialist Celyad is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner Medisun ...

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Nick Paul Taylor Adaptimmune has bagged two milestones from GlaxoSmithKline. The checks landed in Adaptimmune's bank account after it tripled the size of a Phase I/II synovial sarcoma ...
Page 1 of 1312345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS